Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Adebrelimab (Primary) ; Doxorubicin (Primary) ; Mirabegron (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 03 Feb 2025 New trial record